← Leaderboards
Jiangbing Zhou
University Of Alabama At Birmingham
$16,453,834
Attributed
$37,196,636
Total exposure
9
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $11.9M · FY2016–25$20M$15M$10M$5M$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$37,196,636 · 9
By mechanism
UG3$28,381,580 · 2
R01$7,478,171 · 4
R21$920,750 · 2
UH3$416,135 · 1
Top collaborators
- Kevin Navin Sheth8 shared
- Rong Fan5 shared
- Elizabeth Mara Berry-Kravis3 shared
- Yong-Hui Jiang3 shared
- Runhua Runa Liu3 shared
- Nihal C De Lanerolle2 shared
Most similar at University Of Alabama At Birmingham
Same institution · by research overlap
- Eric S Ubil$1,824,622
- Runhua Runa Liu$2,517,658
- Vishnu Anand Cuddapah$714,807
- M R Chambers$2,636,972
- Ralph R Weichselbaum$16,065,057
Others in their field
Top investigators on “Success”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Gerald T Nepom · Benaroya Research Inst At Virginia Mason$298,740,071
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$277,058,716
- Lawrence Corey · Fred Hutchinson Cancer Center$274,406,165
- Barton F Haynes · Duke University$260,353,372
Research focus
SuccessBrainNanoparticleDrug Delivery SystemsTargeted DeliveryClinical ApplicationMediatingPublic HealthMolecularEffective TherapyMouse ModelPharmaceutical PreparationsPenetrationNovel StrategiesTechnologyUnited StatesCellsBaseCell TypeMalignant NeoplasmsDoseCrispr/Cas TechnologyResearch Project GrantsInnovation
Grant awards (32)
A non-viral CRISPR-mediated genome editing delivery platform as a potential therapy for neurogenetic diseases$10,672,633
UG3 · FY2025 · TR
A non-viral CRISPR-mediated genome editing delivery platform as a potential therapy for neurogenetic diseases$10,834,632
UG3 · FY2024 · TR
Ex vivo analysis of human brain tumor cells in a microvascular niche model$491,875
R01 · FY2024 · CA
Targeted delivery of multimodal therapy for reducing prostate cancer disparity$364,267
R01 · FY2024 · CA
Elucidate genetic regulation of GBM differentiation$209,375
R21 · FY2024 · NS · contact PI
A non-viral CRISPR-mediated genome editing delivery platform as a potential therapy for neurogenetic diseases$5,019,038
UG3 · FY2023 · TR
Ex vivo analysis of human brain tumor cells in a microvascular niche model$517,222
R01 · FY2023 · CA
Targeted delivery of multimodal therapy for reducing prostate cancer disparity$371,500
R01 · FY2023 · CA
Improved glyburide therapy via acid- triggered release functional nanoparticles and therapeutic imaging$361,070
R01 · FY2023 · NS · contact PI
Elucidate genetic regulation of GBM differentiation$251,250
R21 · FY2023 · NS · contact PI
Improved glyburide therapy via acid- triggered release functional nanoparticles and therapeutic imaging$13,819
R01 · FY2023 · NS · contact PI
Novel grafted terpolymers for targeted delivery of CRISPR/Cas9- mediated precise genome editing to the brain$626,995
UG3 · FY2022 · NS · contact PI
Ex vivo analysis of human brain tumor cells in a microvascular niche model$526,749
R01 · FY2022 · CA
Novel grafted terpolymers for targeted delivery of CRISPR/Cas9- mediated precise genome editing to the brain$416,135
UH3 · FY2022 · NS · contact PI
Targeted delivery of multimodal therapy for reducing prostate cancer disparity$386,974
R01 · FY2022 · CA
Improved glyburide therapy via acid- triggered release functional nanoparticles and therapeutic imaging$367,550
R01 · FY2022 · NS · contact PI
Improved glyburide therapy via acid- triggered release functional nanoparticles and therapeutic imaging$12,563
R01 · FY2022 · NS · contact PI
Ex vivo analysis of human brain tumor cells in a microvascular niche model$546,939
R01 · FY2021 · CA
Improved glyburide therapy via acid- triggered release functional nanoparticles and therapeutic imaging$367,550
R01 · FY2021 · NS · contact PI
Improved glyburide therapy via acid- triggered release functional nanoparticles and therapeutic imaging$23,031
R01 · FY2021 · NS · contact PI
Novel grafted terpolymers for targeted delivery of CRISPR/Cas9- mediated precise genome editing to the brain$612,488
UG3 · FY2020 · NS · contact PI
Ex vivo analysis of human brain tumor cells in a microvascular niche model$556,102
R01 · FY2020 · CA
Improved glyburide therapy via acid- triggered release functional nanoparticles and therapeutic imaging$371,020
R01 · FY2020 · NS · contact PI
Systemic gene therapy for glioblastoma$364,219
R01 · FY2020 · NS · contact PI
Novel grafted terpolymers for targeted delivery of CRISPR/Cas9- mediated precise genome editing to the brain$615,794
UG3 · FY2019 · NS · contact PI
Improved glyburide therapy via acid- triggered release functional nanoparticles and therapeutic imaging$378,845
R01 · FY2019 · NS · contact PI
Systemic gene therapy for glioblastoma$364,219
R01 · FY2019 · NS · contact PI
Systemic gene therapy for glioblastoma$364,219
R01 · FY2018 · NS · contact PI
Systemic gene therapy for glioblastoma$364,219
R01 · FY2017 · NS · contact PI
MIF20-loaded nanoparticles for TBI treatment$209,375
R21 · FY2017 · NS · contact PI
Systemic gene therapy for glioblastoma$364,219
R01 · FY2016 · NS · contact PI
MIF20-loaded nanoparticles for TBI treatment$250,750
R21 · FY2016 · NS · contact PI